Xeris Biopharma Holdings, Inc. XERS
We take great care to ensure that the data presented and summarized in this overview for Xeris Biopharma Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XERS
View all-
Black Rock Inc. New York, NY10.3MShares$38.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$29.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.34MShares$12.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.88MShares$10.8 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD2.57MShares$9.66 Million3.53% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.1MShares$7.87 Million0.01% of portfolio
-
Caxton Corp Princeton, NJ2.02MShares$7.56 Million43.3% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.95MShares$7.31 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.9MShares$7.14 Million0.0% of portfolio
Latest Institutional Activity in XERS
Top Purchases
Top Sells
About XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Insider Transactions at XERS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Beth Hecht Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+11.72%
|
-
|
|
Jan 31
2025
|
Beth Hecht Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
144,284
-5.46%
|
$432,852
$3.56 P/Share
|
|
Jan 31
2025
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+22.94%
|
-
|
|
Jan 31
2025
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
221,500
-5.4%
|
$664,500
$3.56 P/Share
|
|
Jan 31
2025
|
Kevin Mc Culloch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+9.9%
|
-
|
|
Jan 31
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78,134
-2.51%
|
$234,402
$3.56 P/Share
|
|
Jan 31
2025
|
Kenneth Erland Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,318
-5.87%
|
$123,954
$3.56 P/Share
|
|
Jan 31
2025
|
Steven Pieper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+11.54%
|
-
|
|
Jan 31
2025
|
Steven Pieper Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
177,200
-6.49%
|
$531,600
$3.56 P/Share
|
|
Jan 03
2025
|
Beth Hecht Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,039
-2.31%
|
$96,117
$3.61 P/Share
|
|
Jan 03
2025
|
Steven Pieper Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,059
-2.22%
|
$96,177
$3.61 P/Share
|
|
Jan 03
2025
|
Kenneth Erland Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,401
-3.31%
|
$37,203
$3.61 P/Share
|
|
Jan 03
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,501
-1.53%
|
$73,503
$3.61 P/Share
|
|
Jan 03
2025
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
39,443
-1.84%
|
$118,329
$3.61 P/Share
|
|
Nov 22
2024
|
Steven Pieper Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,483
+1.33%
|
$19,483
$1.55 P/Share
|
|
Aug 12
2024
|
John P. Schmid Director |
BUY
Open market or private purchase
|
Indirect |
4,515
+15.19%
|
$9,030
$2.25 P/Share
|
|
Aug 09
2024
|
John P. Schmid Director |
BUY
Open market or private purchase
|
Indirect |
4,285
+17.16%
|
$8,570
$2.37 P/Share
|
|
Aug 01
2024
|
Kevin Mc Culloch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+8.56%
|
-
|
|
Aug 01
2024
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+9.36%
|
-
|
|
Jul 28
2024
|
Steven Pieper Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,767
-1.03%
|
$29,534
$2.61 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.16M shares |
|---|---|
| Other acquisition or disposition | 103K shares |
| Open market or private purchase | 18.7K shares |
| Exercise of conversion of derivative security | 235K shares |
| Payment of exercise price or tax liability | 818K shares |
|---|